3/18
01:04 am
sndx
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? [Yahoo! Finance]
Low
Report
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? [Yahoo! Finance]
3/12
02:33 pm
sndx
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/9
01:24 pm
sndx
Syndax Pharmaceuticals (SNDX) had its price target raised by JPMorgan Chase & Co. from $33.00 to $45.00. They now have an "overweight" rating on the stock.
Medium
Report
Syndax Pharmaceuticals (SNDX) had its price target raised by JPMorgan Chase & Co. from $33.00 to $45.00. They now have an "overweight" rating on the stock.
3/8
01:31 am
sndx
Medium
Report
3/4
04:01 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/2
02:27 pm
sndx
Syndax Pharmaceuticals (SNDX) had its price target raised by Citigroup Inc. from $51.00 to $57.00. They now have a "buy" rating on the stock.
Low
Report
Syndax Pharmaceuticals (SNDX) had its price target raised by Citigroup Inc. from $51.00 to $57.00. They now have a "buy" rating on the stock.
3/2
03:12 am
sndx
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs [Yahoo! Finance]
2/28
12:43 am
sndx
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? [Yahoo! Finance]
Low
Report
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? [Yahoo! Finance]
2/27
07:03 pm
sndx
Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]
2/27
06:00 pm
sndx
Syndax Pharmaceuticals (SNDX) was given a new $45.00 price target by Stifel Nicolaus.
Low
Report
Syndax Pharmaceuticals (SNDX) was given a new $45.00 price target by Stifel Nicolaus.
2/26
04:22 pm
sndx
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
2/26
04:01 pm
sndx
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/23
07:00 am
sndx
Syndax Announces Participation in March Investor Conferences
Neutral
Report
Syndax Announces Participation in March Investor Conferences
2/19
07:00 am
sndx
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
Low
Report
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
2/15
09:32 pm
sndx
Is Syndax Pharmaceuticals (SNDX) Pricing Reflecting Recent Biotech Reassessment Or Long Term Potential [Yahoo! Finance]
Low
Report
Is Syndax Pharmaceuticals (SNDX) Pricing Reflecting Recent Biotech Reassessment Or Long Term Potential [Yahoo! Finance]
2/12
05:56 am
sndx
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 [Seeking Alpha]
Low
Report
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 [Seeking Alpha]
2/7
02:07 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by analysts at
Wall St
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by analysts at
Wall St
2/5
07:00 am
sndx
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
Low
Report
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
2/4
04:01 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/27
11:45 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Mizuho from $410.00 to $600.00. They now have an "outperform" rating on the stock.
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Mizuho from $410.00 to $600.00. They now have an "outperform" rating on the stock.
1/19
05:21 pm
sndx
Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory [Yahoo! Finance]
1/12
08:55 am
sndx
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/12
07:00 am
sndx
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
1/11
01:03 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at
Wall
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at
Wall
1/7
07:00 am
sndx
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Medium
Report
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.